Catalyst Pharmaceuticals Inc. (CPRX)

6.21
NASDAQ : Health Technology
Prev Close 6.13
Day Low/High 6.00 / 6.82
52 Wk Low/High 1.85 / 7.67
Avg Volume 1.55M
Exchange NASDAQ
Shares Outstanding 102.93M
Market Cap 631.37M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results And Provides Corporate Update

Firdapse ® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla.

Catalyst Pharmaceuticals To Hold Second Quarter 2019 Financial Results Conference Call And Webcast On Thursday, August 8th, 2019

Catalyst Pharmaceuticals To Hold Second Quarter 2019 Financial Results Conference Call And Webcast On Thursday, August 8th, 2019

CORAL GABLES, Fla., July 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.

First Week Of August 16th Options Trading For Catalyst Pharmaceuticals (CPRX)

First Week Of August 16th Options Trading For Catalyst Pharmaceuticals (CPRX)

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPRX options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Insiders Were Right: CPRX Makes New 52-Week High

Insiders Were Right: CPRX Makes New 52-Week High

In trading on Wednesday, shares of Catalyst Pharmaceuticals Inc touched a new 52-week high of $4.06/share. That's a 119.46% rise, or $2.21 per share from the 52-week low of $1.85 set back on 01/02/2019.

CPRX: Insiders Vs. Shorts

CPRX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 01/31/2019 settlement date, and Catalyst Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 13.69 "days to cover" versus the median component at 4.98. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week Of September 20th Options Trading For Catalyst Pharmaceuticals (CPRX)

First Week Of September 20th Options Trading For Catalyst Pharmaceuticals (CPRX)

Investors in Catalyst Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 227 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Commit To Buy Catalyst Pharmaceuticals At $2.50, Earn 13.8% Annualized Using Options

Commit To Buy Catalyst Pharmaceuticals At $2.50, Earn 13.8% Annualized Using Options

Investors eyeing a purchase of Catalyst Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 20 cents.

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

First Week of January 2018 Options Trading For Catalyst Pharmaceuticals (CPRX)

First Week of January 2018 Options Trading For Catalyst Pharmaceuticals (CPRX)

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPRX options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results And Provides Corporate Update

Company to Host Quarterly Conference Call at 8:30 am EDT Tomorrow

First Week Of CPRX June 2018 Options Trading

First Week Of CPRX June 2018 Options Trading

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the June 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of November 17th Options Trading For Catalyst Pharmaceuticals (CPRX)

First Week of November 17th Options Trading For Catalyst Pharmaceuticals (CPRX)

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPRX options chain for the new November 17th contracts and identified the following put contract of particular interest.